These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22766374)

  • 1. PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.
    Slobbe P; Poot AJ; Windhorst AD; van Dongen GA
    Drug Discov Today; 2012 Nov; 17(21-22):1175-87. PubMed ID: 22766374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET.
    van Dongen GA; Poot AJ; Vugts DJ
    Tumour Biol; 2012 Jun; 33(3):607-15. PubMed ID: 22270450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET imaging for tyrosine kinase inhibitor (TKI) biodistribution in mice.
    Fushiki H; Murakami Y; Miyoshi S; Nishimura S
    Methods Mol Biol; 2015; 1219():199-206. PubMed ID: 25308271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging of TKI-target interactions for personalized cancer therapy.
    Poot AJ; Slobbe P; Hendrikse NH; Windhorst AD; van Dongen GA
    Clin Pharmacol Ther; 2013 Mar; 93(3):239-41. PubMed ID: 23340475
    [No Abstract]   [Full Text] [Related]  

  • 5. Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET.
    Bahce I; Yaqub M; Smit EF; Lammertsma AA; van Dongen GA; Hendrikse NH
    Lung Cancer; 2017 May; 107():1-13. PubMed ID: 27319335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Protein tyrosine kinase inhibitors in cancer therapy].
    Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
    Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging.
    Bernard-Gauthier V; Bailey JJ; Berke S; Schirrmacher R
    Molecules; 2015 Dec; 20(12):22000-27. PubMed ID: 26690113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome.
    Yang B; Papoian T
    J Appl Toxicol; 2012 Dec; 32(12):945-51. PubMed ID: 22961481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syntheses and evaluation of carbon-11- and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents.
    Bernard-Gauthier V; Aliaga A; Aliaga A; Boudjemeline M; Hopewell R; Kostikov A; Rosa-Neto P; Thiel A; Schirrmacher R
    ACS Chem Neurosci; 2015 Feb; 6(2):260-76. PubMed ID: 25350780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer.
    Poot AJ; van der Wildt B; Stigter-van Walsum M; Rongen M; Schuit RC; Hendrikse NH; Eriksson J; van Dongen GA; Windhorst AD
    Nucl Med Biol; 2013 May; 40(4):488-97. PubMed ID: 23522977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
    Deng J; Shao J; Markowitz JS; An G
    Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric tyrosine kinase-HDAC inhibitors as antiproliferative agents.
    Uecker A; Sicker M; Beckers T; Mahboobi S; Hägerstrand D; Ostman A; Böhmer FD
    Anticancer Drugs; 2010 Sep; 21(8):759-65. PubMed ID: 20613486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
    Oudard S; Elaidi RT
    Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review.
    Ranieri G; Pantaleo M; Piccinno M; Roncetti M; Mutinati M; Marech I; Patruno R; Rizzo A; Sciorsci RL
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):293-308. PubMed ID: 23768779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.
    Zannetti A; Iommelli F; Fonti R; Papaccioli A; Sommella J; Lettieri A; Pirozzi G; Bianco R; Tortora G; Salvatore M; Del Vecchio S
    Clin Cancer Res; 2008 Aug; 14(16):5209-19. PubMed ID: 18698039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.
    Drenberg CD; Baker SD; Sparreboom A
    Clin Pharmacol Ther; 2013 Mar; 93(3):215-9. PubMed ID: 23419484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
    Hojjat-Farsangi M
    J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two anti-angiogenic TKI-PET tracers, [(11)C]axitinib and [(11)C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents.
    Slobbe P; Poot AJ; Haumann R; Schuit RC; Windhorst AD; van Dongen GA
    Nucl Med Biol; 2016 Oct; 43(10):612-24. PubMed ID: 27497236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a future for Aurora kinase inhibitors for anticancer therapy?
    Carpinelli P; Moll J
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
    Dasanu CA; Padmanabhan P; Clark BA; Do C
    Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.